×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VOR – vor biopharma inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VOR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/25
09:06 am
vor
Vor Biopharma (NASDAQ:VOR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
Medium
Report
Vor Biopharma (NASDAQ:VOR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
11/14
08:09 am
vor
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at HC Wainwright from $55.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at HC Wainwright from $55.00 to $32.00. They now have a "buy" rating on the stock.
11/13
07:23 am
vor
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Medium
Report
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/10
09:56 pm
vor
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
High
Report
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
11/10
04:01 pm
vor
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
High
Report
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
11/8
11:45 am
vor
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
Low
Report
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
11/7
08:00 am
vor
Vor Bio to Participate in Upcoming Investor Conferences
Low
Report
Vor Bio to Participate in Upcoming Investor Conferences
11/3
08:00 am
vor
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
Medium
Report
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/18
04:30 pm
vor
Form SCHEDULE 13G Vor Biopharma Inc. Filed by: Paradigm Biocapital Advisors LP
High
Report
Form SCHEDULE 13G Vor Biopharma Inc. Filed by: Paradigm Biocapital Advisors LP
11/14
06:13 pm
vor
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Low
Report
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
11/12
07:03 am
vor
Form 8-K Vor Biopharma Inc. For: Nov 10
Low
Report
Form 8-K Vor Biopharma Inc. For: Nov 10
11/12
06:08 am
vor
Form 424B5 Vor Biopharma Inc.
Neutral
Report
Form 424B5 Vor Biopharma Inc.
11/7
11:14 am
vor
Form SCHEDULE 13G Vor Biopharma Inc. Filed by: FMR LLC
Low
Report
Form SCHEDULE 13G Vor Biopharma Inc. Filed by: FMR LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: